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136 Poster Session IIof the entire group was 47%. The 5 year survival of patients with (n
5 148) or without (n 5 31) CMV/EBV reactivation was respec-
tively: 50%vs 28% (p5 0.02). This was due to a lower risk of relapse
related death (RRD) in patients with reactivation 19% vs 42% (p5
0.005) and similar transplant related mortality (TRM), 28% vs 27%
(p5 0.8). In multivariate analysis disease phase (\5CR2) predicted
survival (RR 0.33) relapse related death (RR 0.50) and TRM (RR
0.72); CMV/EBV reactivation predicted survival (RR 0.69); and
RRD (RR 0.61); RIC transplants were associated with inreased
RRD (RR 4.56).
In conclusion: reactivation of CMV/EBV is a common event in
our transplant prgram. Possibly because of an early diagnosis and
pre-emptive therapy, TRM is comparable in patients with and with-
out infection. Viral reactivation seems to promote the graft versus
leukemia effect of the transplant.371
CO-TRANSPLANTATION OF HUMAN Tregs AND CD341 CELLS: A PRE-
CLINICAL STUDY
Mahmud, D., Chunduri, S., Mahmud, N., Van den Dries, L.,
Maciejewski, J., Rondelli, D. University of Illinois at Chicago, Chicago,
IL.
Co-transplantation of purified CD341 cells and regulatory T
cells (Tregs) might favor the immune reconstitution and limit the
incidence of graft-versus-host disease and graft rejection in an
HLAmismatched transplant setting. In this study we immunomag-
netically selected human CD41CD251 Tregs, which resulted
.80% FoxP3 positive by flow cytometry, and CB CD341 cells.
Then we tested if Tregs would affect CB CD341 cell clonogenic
activity in-vitro an in-vivo, and if co-incubation of Tregs and
CD341 cells may modify the phenotype and function of Tregs. A
colony-forming cells (CFU-C) assay performed with CD341 cells
mixed with allogeneic Tregs at 1:2 ratio resulted in comparable
numbers of Granulocyte- Macrophage CFU (CFU-GM), burst-
forming unit-erythroid (BFU-E) and CFU-Mix as compared to
cultures with CD341 cells alone (p 5 0.2, p 5 0.5 and p 5 0.5,
respectively)(n5 3 exps). Human CD341 cells were then co-trans-
planted with human CD41CD251 allogeneic Tregs into NOD/
SCID mice at 1:1 and 1:2 ratio. After 6 weeks mice marrow was
harvested and showed a 1.3 6 1.1% (n 5 3 mice) and 1.6 6 0.8%
(n 5 4 mice) engraftment of huCD451 cells, respectively, which
was comparable to the engraftment observed in control animals
transplanted with CD341 cells alone (1.4 6 0.4). Among the en-
grafted huCD451 cells similar proportion of CD331 cells,
CD141 monocytes and CD1c1 dendritic cells were observed in
the three groups of animals. Mixed lymphocyte culture (MLC) ex-
periments showed that irradiated CD341 cells stimulated brisk
proliferative responses of allogeneic CD41CD25- cells, but not
of Tregs (n 5 3 exps). After incubation with CD341 cells in the
presence of IL2, on average.80%CD41CD251 cells maintained
the intracellular expression of FoxP3 and surface expression of
CD62L and CD152 (n 5 3 exps). Tregs and CD341 cells were
then isolated from the same CB unit. A primary MLC with irrad
CB CD341 cells and HLA mismatched PB T cell responders was
performed w/wo the addition of CB Tregs at 1:1 ratio with
CD341 cells. A 686 14% (n5 3 exps) inhibition of T cell alloreac-
tivity to CD341 cells was observed in MLC with Tregs. Our find-
ings demonstrate that co-transplantation of CD341 cells andTregs
results in normal stem cell engraftment and potentially reduces
T cell alloreactivity. These results will prompt the design of new
strategies in transplantation of HLA incompatible stem cells by
combining donor-derived CD341 and CD41CD251 cells.372
LEUKEMIC BLASTS ACTING AS HOST ANTIGEN PRESENTING CELLS
TRIGGER A COMBINED CD4 AND CD8 ALLO-IMMUNE RESPONSE DI-
RECTED AGAINST MISMATCHED HLA CLASS I
Amir, A., Hagedoorn, R.S., Marijt, E.A.F., Willemze, R.,
Falkenburg, J.H.F., Heemskerk, M.H.M. Leiden University Medical
Center, Leiden, Netherlands.Single locus HLAmismatched stem cell transplantation (SCT) is
applied in patients with hematological malignancies who may ben-
efit from allogeneic transplantation but lack an HLA-matched do-
nor. Donor lymphocyte infusion (DLI), applied in patients with
mismatched SCT, have a high likelihood of inducing graft versus
host disease (GVHD), however not all patients develop GVHD.
In view of the high frequency of allo-HLA reactive T-cells, and al-
most all nucleated cells express HLA class I, one would expect all
single HLA class I mismatched transplanted patients to develop se-
vere GVHD. We hypothesized therefore that the presentation of
the HLA class I mismatched allele on cells of the patient is not suf-
ficient to elicit an effective allo-immune response.We characterized
the allo-immune response in a patient with acute myeloid leukemia
who was treated with a T-cell depleted SCT from a sibling donor
who was HLA identical except for HLA-A2. Six months after
SCT, DLI was given for mixed chimerism. No clinical response
and no GVHD developed. 12 months after SCT the AML relapsed
with 9% blasts in bone marrow for which a second DLI was given.
Five weeks after the DLI the patient died of grade IVGVHD. Dur-
ing the GVHD conversion to donor chimerism developed. In pe-
ripheral blood of the patient 90% of CD8 and 40% of CD4
donor T-cells were activated as determined by HLA-DR expres-
sion. To analyze the nature of the immune response, the activated
CD8 and CD4 donor T-cells were single cell sorted, expanded
and tested for alloreactivity. Most CD8T-cell clones were alloreac-
tive and restricted to the allo-HLA-A2 molecule. 26% of the CD4
clones were alloreactive, and these clones recognized epitope 103–
120 of the hypervariable region of HLA-A2 in the context of HLA-
DR1. BothT cell responses were highly polyclonal. Prior to the first
DLI, only HLA class I expressing T-cells and non-hematopoietic
patient derived cells were present, these cells were isolated and
were shown to activate the CD8 clones but not the CD4 clones.
Leukemic blasts isolated at the time of the second DLI, expressed
HLA-DR, and activated the CD4 as well as the CD8 clones.We hy-
pothesize that the HLA class II expression on hematopoietic cells of
the patient at the time of the relapse was essential for the develop-
ment of GVHD. These results indicate a role for patient leukemic
blasts acting as host APCs in initiating the GVHD by activating
both a CD4 andCD8T-cell response in anHLA class Imismatched
setting.373
WHAT IS THE ROLE FOR REGULATORY T-CELLS AFTER NONMYELOA-
BLATIVE CONDITIONING?
Humblet-Baron, S., Castermans, E., Vanbellighen, J.-F., Hannon, M.,
Jacobs, N., Beguin, Y., Baron, F. University of Liege, Liege, Belgium.
Purpose:We investigated the association between regulatory T-
cell (T-reg) levels and chronic graft-versus-host disease (GVHD)
after allogeneic hematopoietic stem cell transplantation following
nonmyeloablative conditioning. Methods: Data from 34 patients
given nonmyeloablative conditioning as treatment for hematologi-
cal malignancies were analyzed. Conditioning regimens consisted
of low-doseTBI with or without fludarabine (n5 28), or cyclophos-
phamide plus fludarabine (n 5 6). T-reg (CD41FoxP31) levels on
day 100 were determined by flow cytometry. Chimerism levels
among total white blood cells, CD31 T-cells and
CD41CD251CD127dim/neg regulatory T-cells were determined
by multiplex STR PCR or X-Y FISH. Thymic function was deter-
mined by assessing sjTREC levels. Results: Median T-reg fre-
quency (i.e. % of lymphocytes that were CD41FoxP31), T-reg
level and T-reg chimerism on day 100 were 1.7% (0.3–9%), 14
cells/mL (3–127 cells/mL), and 90% (46–100%) respectively. Chi-
merism levels among CD41CD251CD127dim/neg regulatory T-
cells did not correlate with chimerism levels among total white
blood cells (r 5 0.29, P 5 0.31), nor CD31 T-cells (r 5 0.38,
P 5 0.18). Fifteen patients develop chronic GVHD, and 19 did
not. Analyzing data as median, there was not any correlation be-
tween low T-reg frequency, T-reg levels or T-reg chimerism levels
on day 100 and high incidence of chronic GVHD (HR 5 1.7, P 5
0.25; HR 5 1.2, P 5 0.70; and HR 5 0.5, P 5 0.32, respectively).
Finally, T-reg levels correlated weakly with sjTREC levels both as-
sessed on day 100 after transplantation (r 5 0.37, P 5 0.04).
